North India Statesman
[ad_1]
News India Live, Digital Desk: Shares of Promotion Mother’s International and Elkem Laboratories are expected to be in the discussion on May 30, 2025, on Friday as the two companies have declared their Q4 2024-25 results on Thursday. The Q4 net profit of Elkem Laboratories increased by 6 percent to Rs 322 crore, while the January-March quarter’s profit increased by 19 percent to Rs 1,050 crore.
Samardhana Madrasan International on Thursday Shares closed at Rs 152.15 per share with a rise of 2.29 per cent on BSE. At the same time, the shares of Elkem Laboratories closed at Rs 5,325 per share.
Today, the shares of Samvardhana Mother’s International are expected to be in the discussion as the auto component manufacturer has declared his Q4 results of 2024-25. In the January-March quarter of FY 25, the company increased by 19 percent to Rs 1,050 crore in the January-March quarter, compared to Rs 879 crore for the same period in FY 2023-24.
The regulatory filing states that the total income from the operation of Promotion Madrasan increased from Rs 27,666 crore to Rs 29,317 crore.
For the entire financial year 2025, the company recorded a consolidated PAT of Rs 3,803 crore, while in 2023-24 it was Rs 2,716 crore. The revenue increased from Rs 98,692 crore to Rs 1,13,663 crore.
Madarson Chairman Vivek Chand Sehgal said, “Our performance reflects the flexibility and adaptability of our business. Taking advantage of its strong engineering and manufacturing expertise, we are fully prepared to meet the needs of our customers, which prepares us for long -term sustainable development.”
Alchem Laboratories Q4 Results 2024-25
In its Q4 results 2024-25, Elkem Laboratories mentioned that its consolidated net profit increased by 6 percent to Rs 322 crore compared to the net profit of Rs 304 crore in the final quarter of 2023-24 FY.
The company’s operational revenue increased to Rs 3,144 crore in the January-March quarter of FY 2025, compared to Rs 2,936 crore in the same period a year ago.
In the regulatory filing, the company said that its consolidated net profit in FY 2024-25 was Rs 2,215 crore, while in FY 2024 it was Rs 1,811 crore. Revenue increased to Rs 12,964 crore in FY 2025, while in FY 2023-24 it was Rs 12,667 crore.
Alchem CEO Vikas Gupta said, “Our domestic business is constantly gaining momentum, which is strengthening our confidence in its long -term development path. This performance is inspired by strong implementation and target initiatives in our domestic operations.”
Gupta said, “As we are moving, we are focusing on strategic development opportunities and operational excellence to get permanent returns.”
The company said that its board has approved the final dividend of Rs 8 on each stock worth Rs 2 for the financial year ended 31 March 2025.
8th Pay Commission: Possible surge in salary of central personnel, know how much can increase
